# US 2026/0091038 A1 · Compositions and methods for enhancing wnt signaling for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091038 A1
- Document ID: US20260091038A1
- Status: Published application
- Kind: A1
- Application number: 19/294,146
- Filed: 2025-08-07
- Published: 2026-04-02
- Earliest claimed: 2021-10-07
- Assignees: Massachusetts Institute of Technology; The General Hospital Corporation
- Applicants: Massachusetts Institute of Technology; The General Hospital Corporation
- Inventors: George Eng; Omer Yilmaz; Jonathan Braverman
- Web page: https://patentgrep.com/patent/US20260091038A1

## CPC

- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/497: containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- C07K 14/475: Growth factors; Growth regulators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and compositions for enhancing Wnt signaling pathway activities in a tissue of a subject have been developed for the treatment of cancer, in particular cancers with one or more mutations in the APC (adenomatous polyposis coli) gene. Preferably, the amount of the compositions for enhancing Wnt signaling does not reduce or inhibit proliferation or viability of normal healthy cells in the subject. In some embodiments, pharmaceutical compositions including an effective amount of one or more GSK-3 inhibitors are administered to reduce cancer cell proliferation or viability in a subject. A preferred GSK-3 inhibitor is LY2090314 encapsulated within, or associated with nanoparticles. Dosage forms of LY2090314 encapsulated within, or associated with nanoparticles for administration are also described.

## Claims

### Claim 1

A method for treating adenoma, or cancer with overactivated Wnt in a subject in need thereof, comprising administering to the subject an effective amount of a composition for increasing Wnt signaling activity in adenoma or cancer cells of the subject to reduce adenoma or cancer cell proliferation and/or reduce adenoma or cancer cell viability in the subject,
wherein the composition for increasing Wnt signaling activity comprises a glycogen synthase kinase 3 (GSK-3) inhibitor, or a Wnt agonist, or a combination of a GSK-3 inhibitor and a Wnt agonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount of the composition does not reduce the proliferation and/or viability of healthy cells in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition for increasing Wnt signaling activity comprises a Wnt agonist and a synthase kinase 3 (GSK-3) inhibitor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises a GSK-3 inhibitor comprising a structure

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises a GSK-3 inhibitor encapsulated within and/or associated with a delivery vehicle that increases the serum half-life of the GSK-3 inhibitor as compared to the serum half-life of the same amount of the GSK-3 inhibitor alone.

### Claim 7 (depends on 6)

The method of claim 6, wherein the delivery vehicle is a nanoparticle or microparticle selected from the group consisting of a liposome, a polymeric particle, a virus-like-particle, and a protein nanostructure.

### Claim 8 (depends on 7)

The method of claim 7, wherein the polymeric nanoparticle comprises poly(lactic-co-glycolic acid) (PLGA) and/or polyhydroxyalkanoates.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition comprises a for increasing Wnt agonist,
wherein the Wnt agonist comprises an isolated Wnt-3a protein, or an isolated R-Spondin 1 or an isolated R-Spondin 3 protein.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the adenoma or cancer cells have one or more mutations in the adenomatous polyposis coli (APC) gene.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of colon cancer, rectal cancer, peritoneal carcinomatosis, pancreatic cancer, adenocarcinoma, ovarian cancer, multiple myeloma, and sarcomas, of pancreas, bone, bladder, brain, breast, cervical, esophageal, kidney, liver, lung, nasopharyngeal, prostate, skin, stomach, and uterine.

### Claim at position 13

-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the composition is administered to the subject by a route selected from the group consisting of intravenous, intramuscular, intravascular, intrathecal, intraperitoneal, subcutaneous, intraarticular, and oral.

### Claim 16 (depends on 1)

The method of claim 1, further comprising administering to the subject one or more selected from the group consisting of adoptive T cell therapy, a cancer vaccine, surgery, radiation therapy, a chemotherapeutic agent, an anti-infective agent, and combinations thereof.

### Claim at position 16

-20. (canceled)

### Claim 21

A method of increasing regeneration of colon tissue in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition for enhancing Wnt signaling pathway activity in normal cells of the subject,
wherein the composition for increasing Wnt signaling activity comprises a glycogen synthase kinase 3 (GSK-3 inhibitor), or a Wnt agonist, or a combination of a GSK-3 inhibitor and a Wnt agonist.

### Claim at position 18

-24. (canceled)

### Claim 25

A dosage form for injection or for oral administration comprising a GSK-3 inhibitor, or a Wnt agonist, or a combination of a GSK-3 inhibitor and a Wnt agonist in an amount effective to increase Wnt signaling activity in adenoma or cancer cells of a subject and reduce adenoma or cancer cell proliferation and/or reduce adenoma or cancer cell viability in the subject.

### Claim 26 (depends on 25)

The dosage form of claim 25, wherein the amount effective to increase Wnt signaling activity in adenoma or cancer cells does not reduce the proliferation and/or viability of healthy cells in the subject.

### Claim 27 (depends on 25)

The dosage form of claim 25, comprising a GSK-3 inhibitor comprising a structure

### Claim 28

(canceled)

### Claim 29 (depends on 25)

The dosage form of claim 25, comprising a Wnt agonist and a GSK-3 inhibitor.

### Claim 30 (depends on 1)

A kit comprising a GSK-3 inhibitor and/or a Wnt agonist in an amount effective to increase Wnt signaling activity in adenoma or cancer cells of a subject and reduce adenoma or cancer cell proliferation and/or reduce adenoma or cancer cell viability in the subject, and instructions for use according to claim 1.

### Claim at position 25

-40. (canceled)

### Claim 41 (depends on 25)

The dosage form of claim 25, comprising a Wnt agonist,
wherein the Wnt agonist comprises an isolated Wnt-3a protein, or an isolated R-Spondin 1 or R-Spondin 3 protein.

### Claim at position 27

42-43. (canceled)

### Claim 44 (depends on 3)

The method of claim 3, wherein the GSK-3 inhibitor and the Wnt agonist are administered via different routes and/or times within a treatment cycle.

### Claim 52

(canceled)
